Navigation Links
Octapharma Announces octagam® 5% Again Available for U.S. Purchase
Date:11/30/2011

unity for patient tolerability," said Octapharma USA President Flemming Nielsen. "We have seen over the last year that there are industry-wide concerns over TEEs connected with multiple immune globulin products that remained on the market while we have implemented enhanced safety measures for octagam® 5%. Industry-wide, immune globulin products can lead to TEEs in approximately 1 individual or less for every 10,000 treatments. But our 10-month analysis of octagam® in nearly 60,000 treatments internationally showed that octagam® outperformed this industry benchmark with no reported TEEs."

Octapharma's estimate of 60,000 octagam® 5% and octagam® 10% patient treatments is based on reported global sales of 1.7 million grams, not on actual recorded patient treatment sessions. The number of treatments is based on average patient utilization per treatment. The data has not been submitted to the FDA for evaluation.

The FDA approval to return octagam® 5% to the U.S. market was based on changes Octapharma has made in the manufacturing process and the company's decision to implement a quality control test on every batch of product that is released to the marketplace for the absence of thrombogenic potential. Additionally,

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
5. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
9. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
10. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
11. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, ... a vegetable-glycol solution for use in portable vaporizers, ... the active ingredients in cannabis, cannabidiol offers consumers ... vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which are ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... July 11, 2014 The consumer marketing ... across industry sectors to better identify winning tools ... to engage with and understand consumers, as new ... make critical purchasing decisions. According ... LLC, one area where organizations can observe a ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... , SOUTH SAN FRANCISCO, Calif., July 8 Rigel Pharmaceuticals, ... Company plans to host a conference call on Thursday, July ... Members of Rigel,s senior management team and the principal investigator ... 2b TASKi2 clinical trial of R788 in rheumatoid arthritis, the ...
... OAKS, Calif., July 7 Amgen (Nasdaq: ... head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in ... advanced breast cancer met its primary and secondary endpoints ... was demonstrated for both delaying the time to the ...
Cached Medicine Technology:Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... allegations continue to move forward in the federal ... District of Pennsylvania, Bernstein Liebhard LLP reports. According ... District Judge Lawrence F. Stengel has ordered the ... things, Judge Stengel found that the witness’s testimony ...
(Date:7/12/2014)... Casinos in Australia have ... from international and online casinos. Revenue is estimated to ... years through 2014-15. Greater per capita gambling expenditure has ... Rises in discretionary income levels have also assisted revenue ... items such as casino gambling services. Revenue is estimated ...
(Date:7/12/2014)... -- If you make exercise fun, you,ll eat less after ... adults were led on a 1.4-mile walk and were either ... walk. The participants were given lunch after the walk, and ... 35 percent more chocolate pudding for dessert than those who ... experiment, 46 adults were given mid-afternoon snacks after their walk. ...
(Date:7/12/2014)... (HealthDay News) -- Burn injuries increase in the summer as ... burn experts. Among those most vulnerable to these seasonal fire ... and often get burned by putting their hands on the ... the burn unit at Loyola University Medical Center in Maywood, ... adage of ,When you play with fire, you get burned, ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 "The second ... it’s uncomfortable and painful to wear shoes," said an inventor ... special sock that prevents this from happening. , He then ... effective way to prevent the second and big toes from ... endurance while wearing shoes. Ergonomic and easy to use, it's ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Burn Injuries More Common in Summer 2
... highly effective in preventing the behavioral and academic problems ... a five-year study led by researchers at Lehigh Universitys ... and funded by the National Institute of Mental Health ... children aged 3 to 5 who have shown significant ...
... Diabetes patients could benefit from new research at the ... the intestine that can taste the sugar content of ... receptor that senses sugar and artificial sweeteners is not ... intestine. The discovery will open new avenues for the ...
... misinformation onlineconsequences could be deadly , The Internet ... to spread false ideas about HIV/AIDS, which could have ... paper in PLoS Medicine. , "It may seem remarkable ... is still denial that the virus is the cause ...
... with organ transplants, resigned to a lifetime of anti-rejection ... respite, say researchers at Lucile Packard Children,s Hospital and ... blood sample, the scientists have identified for the first ... small group of patients who beat the odds and ...
... were more likely to be uninsured or covered by ... report in the August issue of Archives of Otolaryngology-Head ... Laryngeal [voice box] cancer is diagnosed in nearly 10,000 ... is among the most common cancers in the upper ...
... STANFORD, Calif. - As U.S. policy experts continue to ... a new study from the Stanford University School of ... group of patients reduce their overall risk of heart ... a cost-effective way. , Case management makes use of ...
Cached Medicine News:Health News:Non-medicinal treatment touted for pre-schoolers with ADHD 2Health News:Non-medicinal treatment touted for pre-schoolers with ADHD 3Health News:Discovery of 'sugar sensor' in intestine could benefit diabetes 2Health News:HIV denialists spread misinformation online -- consequences could be deadly; and more 2Health News:Study provides hope that some transplant patients could live free of anti-rejection drugs 2Health News:Study provides hope that some transplant patients could live free of anti-rejection drugs 3Health News:Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 2Health News:Stanford study highlights cost-effective method of lowering heart disease risks 2Health News:Stanford study highlights cost-effective method of lowering heart disease risks 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: